← GPCalc

NICE Asthma Calculator

BTS/NICE/SIGN NG245 Asthma: diagnosis, monitoring and chronic asthma management (2024) · inhalers from the Cheshire & Merseyside formulary

Scenario

Patient

FeNO & eosinophils

Objective tests

Enter results as they come back – the plan shows the next test in the NICE sequence.

NICE-recommended plan

Enter the age and choose diagnosis or review to see the plan.

Decision support only, based on BTS/NICE/SIGN NG245 (2024). Licensing of AIR and MART varies by inhaler and age – check the SPC. Inhaler choices follow the Cheshire & Merseyside APG formulary (checked October 2026). It does not replace clinical judgement or the full guideline. Acute asthma attacks need urgent assessment.

Quick reference

Diagnosis – objective tests
Over 161. Eosinophils above lab range or FeNO ≥50 ppb → asthma
2. Bronchodilator reversibility: FEV1 ↑ ≥12% and ≥200 mL (or ≥10% predicted)
3. PEF variability ≥20% over 2 weeks (if spirometry delayed)
4. Still suspected → refer for bronchial challenge (1.2.1–1.2.4)
5–161. FeNO ≥35 ppb
2. FEV1 ↑ ≥12% (or ≥10% predicted)
3. PEF variability ≥20%
4. HDM skin prick or total IgE: not sensitised = exclude; sensitised/raised + eosinophils >0.5 = asthma
5. Doubt → paediatric specialist (1.2.5–1.2.9)
Under 5Treat as suspected asthma (ICS trial if indicated); test from age 5 (1.3.1–1.3.3)

Never diagnose without a suggestive history and a positive objective test; code as suspected until then (1.1.2).

Treatment pathway – age 12 and over
  1. As-needed AIR (low-dose ICS/formoterol) – or low-dose MART if highly symptomatic (1.7.1, 1.7.2)
  2. Low-dose MART (1.7.3)
  3. Moderate-dose MART (1.7.4)
  4. Check FeNO and eosinophils: raised → specialist. Not raised → trial LTRA or LAMA 8–12 weeks, then the other (1.7.5)
  5. Specialist in asthma care (1.7.6); also anyone uncontrolled on high-dose ICS (1.7.11)

Older-pathway patients: SABA only → AIR; uncontrolled on low or moderate ICS(±LABA) → low or moderate MART (1.7.7–1.7.10).

Children 5–11 and under 5

5–11: paediatric low-dose ICS twice daily + SABA → paediatric low-dose MART (if able) → moderate MART → specialist. If MART not manageable: add LTRA trial and/or paediatric low → moderate ICS/LABA + SABA → specialist (1.8.1–1.8.7).

Under 5: 8–12 week paediatric low-dose ICS trial if indicated; stop if resolved and review in 3 months; restart if symptoms return; moderate ICS + LTRA trial; refer if still uncontrolled (1.9.1–1.9.6).

Control, risk and review
  • Each review: symptoms, time off work/school, reliever use (check prescriptions), oral steroid courses, ED visits and admissions (1.5.1). Consider ACQ/ACT questionnaires (1.5.2).
  • Uncontrolled: any exacerbation needing oral steroids, reliever ≥3 days/week, or night waking ≥1/week.
  • Poor-outcome risk: >2 SABA inhalers/year, ≥2 oral steroid courses/year, ≥2 ED visits or any admission (1.15.1).
  • Review at least yearly and after any attack, with a written action plan (1.16.1, 1.14.2). Review 8–12 weeks after any change (1.6.4).
  • Step down when well controlled, 8–12 weeks between steps (1.10).